In 2001, sequencing the first human genome cost roughly $100 million and took 13 years. By 2026, Element Biosciences and Ultima Genomics offer whole-genome sequencing for under $200, and a single NovaSeq X Plus can sequence 20,000 human genomes per year.

The result is a data avalanche. Public omics datasets have grown from approximately 50 in 2010 to over 12,000 in 2025 — a 240x increase in 15 years. The UK Biobank alone generated 30 petabytes of data when it released whole-genome sequences for 500,000 participants in 2024. The All of Us Research Program in the US has sequenced 400,000+ genomes and is targeting 1 million.

Sequencing is no longer the bottleneck. Data analysis is.

The Dataset Explosion

The dataset expansion is not uniform. Genomics still dominates in absolute numbers (6,000 datasets), but metabolomics — the study of small-molecule metabolites — has grown 550x from a tiny base. This reflects the maturation of mass spectrometry technologies and the growing interest in the microbiome, exposome, and lipidomics as windows into health and disease.

Multi-omics integration — combining genomics, transcriptomics, proteomics, and metabolomics from the same samples — is the fastest-growing segment. A growing number of studies collect all four data types from the same cohort, enabling models that capture the full chain from genotype to phenotype. These studies are the most data-intensive (easily 50+ terabytes per cohort) and the most analytically demanding.

Tool Adoption Patterns

R/Bioconductor remains the most-used bioinformatics environment, but its growth has plateaued at ~72% adoption. Python-based tools (Scanpy for single-cell data, PyTorch for deep learning models) are growing rapidly — from 52% to 68% in two years. The fastest growth is in cloud APIs (22% to 38%), as institutions move from on-premise analysis to cloud-based workflows offered by DNAnexus, Seven Bridges, and Terra.bio.

The Python shift is driven by the demands of machine learning. Most of the high-impact computational biology papers in 2024-2025 use deep learning models implemented in PyTorch or JAX — frameworks that are poorly supported in R. If the current trend continues, Python will overtake R as the dominant bioinformatics language by 2028.

The Single-Cell Revolution

The single-cell revolution deserves its own analysis. In 2016, the state of the art was analyzing tens of thousands of cells per experiment. In 2025, Parse Biosciences demonstrated a protocol called Evercode that can profile 300 million cells in a single experiment. The cost per cell has dropped from approximately $0.50 (2016) to under $0.01 (2025).

This is not an incremental improvement. It's a phase change. With 300 million cells, you can profile every major cell type in the human body — across multiple individuals — in a single experiment. Spatial transcriptomics (which maps gene expression to physical location in tissue) adds another dimension, with 22% CAGR in publications since 2020.

The computational challenge is staggering. A 300-million-cell dataset requires petabyte-scale storage, GPU clusters for dimensionality reduction and clustering, and entirely new algorithms for visualization and interpretation. The field is rapidly outgrowing standard analysis pipelines.

Organizational Implications

A 2025 survey of 87 biotech organizations found that companies where the Chief Scientific Officer (not the CTO or CIO) drives data platform strategy achieve 68% adoption after one year compared to 31% for engineering-led platforms. Scientists who feel ownership of their data infrastructure use it. Those who have infrastructure imposed on them don't.

The finding is counterintuitive. One would expect that data platforms are an engineering problem. But the data shows that bioinformatics is most effective when scientists — not engineers — decide what tools to build and how to integrate them. The engineers execute; the scientists prioritize. The companies that invert this hierarchy waste 2-3x more budget on unused platform features.

The Scaling Question

The central question for bioinformatics in 2026 is whether the analysis infrastructure can scale as fast as the data. Sequencing throughput is growing at 40-50% CAGR (approaching a Moore's Law-like trajectory). Compute costs are falling at 20-30% CAGR for CPUs but only 5-10% CAGR for premium GPU instances. The analysis cost per genome, which was once a rounding error compared to sequencing cost, now exceeds the sequencing cost for most projects.

The field needs more efficient algorithms, not just more compute. Single-cell analysis pipelines optimized for GPU acceleration (like Rapids-singlecell) are showing 50-100x speedups over CPU-based methods. If this trend continues — algorithms that scale sub-linearly with data size — the analysis bottleneck can be managed. If it doesn't, the cost of computation will become the dominant cost of genomics.

---

Data Sources: NCBI GEO and SRA database statistics, Parse Biosciences press releases (2025), UK Biobank data release documentation (2024), All of Us Research Program data dashboard. Tool adoption rates from survey of 250+ bioinformatics core facilities and computational biology labs (BioTeam, 2025). Scientist-led platform adoption data from independent survey of 87 biotech organizations.

About the Author: Martin DAVILA is a bioeconomy analyst and the founder of Bioinfometrics.